Geode Capital Management’s Terns Pharmaceuticals TERN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.09M | Buy |
1,633,349
+59,145
| +4% | +$221K | ﹤0.01% | 2633 |
|
|
2025
Q1 | $4.35M | Buy |
1,574,204
+57,726
| +4% | +$159K | ﹤0.01% | 2726 |
|
|
2024
Q4 | $8.4M | Buy |
1,516,478
+308,999
| +26% | +$1.71M | ﹤0.01% | 2473 |
|
|
2024
Q3 | $10.1M | Buy |
1,207,479
+85,617
| +8% | +$714K | ﹤0.01% | 2373 |
|
|
2024
Q2 | $7.64M | Buy |
1,121,862
+255,941
| +30% | +$1.74M | ﹤0.01% | 2488 |
|
|
2024
Q1 | $5.68M | Buy |
865,921
+25,462
| +3% | +$167K | ﹤0.01% | 2631 |
|
|
2023
Q4 | $5.46M | Buy |
840,459
+52,344
| +7% | +$340K | ﹤0.01% | 2658 |
|
|
2023
Q3 | $3.96M | Buy |
788,115
+604
| +0.1% | +$3.04K | ﹤0.01% | 2760 |
|
|
2023
Q2 | $6.89M | Buy |
787,511
+482,795
| +158% | +$4.22M | ﹤0.01% | 2521 |
|
|
2023
Q1 | $3.61M | Buy |
304,716
+127,068
| +72% | +$1.5M | ﹤0.01% | 2777 |
|
|
2022
Q4 | $1.81M | Buy |
177,648
+8,800
| +5% | +$89.6K | ﹤0.01% | 3089 |
|
|
2022
Q3 | $994K | Buy |
168,848
+89,524
| +113% | +$527K | ﹤0.01% | 3389 |
|
|
2022
Q2 | $196K | Sell |
79,324
-99,987
| -56% | -$247K | ﹤0.01% | 4284 |
|
|
2022
Q1 | $532K | Sell |
179,311
-1,624
| -0.9% | -$4.82K | ﹤0.01% | 3901 |
|
|
2021
Q4 | $1.28M | Sell |
180,935
-12,401
| -6% | -$87.7K | ﹤0.01% | 3587 |
|
|
2021
Q3 | $2.01M | Buy |
193,336
+50,267
| +35% | +$524K | ﹤0.01% | 3348 |
|
|
2021
Q2 | $1.75M | Buy |
143,069
+12,806
| +10% | +$157K | ﹤0.01% | 3325 |
|
|
2021
Q1 | $2.87M | Buy |
+130,263
| New | +$2.87M | ﹤0.01% | 3084 |
|